Rafael Holdings Reports Q3 FY2026 Results, Reduces Debt by $3.5M, Confirms 12-Month Cash Runway

summarizeSummary

Rafael Holdings reported a Q3 FY2026 net loss of $4.2 million, alongside a significant $3.5 million gain from debt settlement and a confirmed cash runway of at least 12 months. The company also highlighted the recent completion of its pivotal Phase 3 study for Trappsol® Cyclo™.

check_boxKey Events

• Q3 Financial Performance

  Net loss attributable to Rafael Holdings, Inc. was $4.2 million for Q3 FY2026, an improvement from $4.8 million in Q3 FY2025. Nine-month net loss increased to $20.5 million from $18.4 million.

• Debt Settlement Gain

  The company recognized a $3.5 million gain by settling an $8.5 million creditor payable for an upfront cash payment of $0.4 million and contingent future payments.

• Cash Position & Runway

  Cash and cash equivalents decreased to $30.5 million as of April 30, 2026, from $52.8 million on July 31, 2025. Management expects this cash to be sufficient for at least the next 12 months.

• Increased R&D Investment

  Research and development expenses significantly increased to $16.9 million for the nine months ended April 30, 2026, up from $5.3 million in the prior year, primarily driven by Cyclo's R&D activities.

auto_awesomeAnalysis

This quarterly report provides a comprehensive financial update, highlighting a significant $3.5 million gain from debt settlement which improves the balance sheet. While the company continues to report losses, the substantial increase in R&D expenses reflects ongoing investment in its lead drug candidate, Trappsol® Cyclo™, which recently completed its pivotal Phase 3 study. The confirmation of a 12-month cash runway provides near-term financial stability. The positive progress in the lead clinical program, coupled with the debt reduction, offers a more optimistic outlook despite continued operational losses.